

Comparative Biosciences Inc.





The Reliable Resource for the Biomedical Community

Featured Histology Capabilities at CBI

Assessment of neural degeneration and apoptosis in neonatal brains of primates and smaller laboratory animals treated with ketamine

Apoptosis and neural degeneration stains

- Activated Caspase 3
- TUNEL
- Fluoro Jade
- Silver stains

::::

For more information, contact Mike Zamora <u>mike_zamora@compbio.com</u>

Quick Links

Contact Us Our Website About CBI

Join Our Mailing List!

Comparative Biosciences, Inc. 786 Lucerne Drive

CBI Welcomes Dr. Alireza Ebrahimnejad, our new immunohistochemistry and pathology scientist

New Drugs Approved

May 13, 2011 -- The FDA approved a new drug today called Victrelis (boceprevir) (Merck) to treat certain adults with chronic <u>hepatitis</u> C. Another protease inhibitor, called telaprevir, is also up for consideration by the FDA as a treatment for Hepatitis C (Vertex Pharmaceuticals.

Laser-induced choroidal neovascularization model in rabbits


CBI is proud to announce that we have developed and validated Choroidal а Laser-Induced Neovascularization Model The in Rabbits. development of this model is the result of nearly 2 years of investigation and experimentation. In this model, we place 10-15 lesions in the retina using a unique lasering process developed by CBI. The lesions form consistently and are composed of a fibrovascular plaque containing new small capillaries typical of neovascularization. Rabbits are examined funduscopically and histopathologically. Lesions assessed are histomorphometrically for area and volume of lesion size. Treatment is reflective of the individual study protocol.

Below on the left is a fundus photograph of lesions at 2 weeks. On the right is a correlative Subretinal neovascular plaque typical of the lesion.

May 2011

Sunnyvale, CA 94085

Phone: 408.738.9260 Fax: 408.738.9278



For information on pre-clinical ophthalmic pharmacokinetics, efficacy modeling and toxicology services offered at CBI, contact Mike Zamora, Business Development Manager

> Tel: 408-738-9265 Email: <u>mike_zamora@compbio.com</u>